Fondo morado.jpg
Fondo Azul.jpg
Fondo morado.jpg

We Believe


That Alzheimer’s disease can be treated, and the first step in that direction is having a reliable and accurate diagnostic even before the first symptoms occur. Also having a good prognosis tool is key to find the right treatment

Neurognos is developing a promising Alzheimer’s disease diagnostic strategy utilizing cutting edge technology and developing a detection and prognosis test solution. We will be able to provide key information empowering physician and patients allowing them to treat the disease in the most effective way

SCROLL DOWN

We Believe


That Alzheimer’s disease can be treated, and the first step in that direction is having a reliable and accurate diagnostic even before the first symptoms occur. Also having a good prognosis tool is key to find the right treatment

Neurognos is developing a promising Alzheimer’s disease diagnostic strategy utilizing cutting edge technology and developing a detection and prognosis test solution. We will be able to provide key information empowering physician and patients allowing them to treat the disease in the most effective way

The Alzheimer Problem

Today, an estimated 35 million people worldwide (MINSAL), 5 million American (Alzheimer’s Association), 500,000 Canadian (Alzheimer Society of Toronto) and 117,000 Chileans are living with Alzheimer’s disease, and according to data from the OECD they expects these figures to double in the next 20 years. In 2014, the direct costs of caring for people living with the disease is estimated to total well over 210 billion dollars just in the U.S. alone.

The Alzheimer's disease therapeutics and diagnostics market will reach 9.6 billion dollars in 2014 with revenue showing strong overall growth to 2024, particularly beyond 2018. Overall, the forecast for Alzheimer's disease, including disease-modifying therapeutics, therapeutics that treat related symptoms, diagnostics and imaging, is set to increase exponentially (Alzheimer's Disease Therapeutics and Diagnostics Market Forecast 2014-2024, visiongain).

The Problem of Diagnosis

screenshot2.png

Alzheimer's many different causes 

Preventing Alzheimer's disease remains a critical unmet need for millions of people worldwide that's why counting with and reliable method to detect Alzheimer's and other neurodegenerative disease at the right time (before even the first symptoms) is critical for our society.

Most people living with Alzheimer's are not aware of their diagnosis. Despite widespread recognition of the benefits of clear and accurate disclosure of the disease, less than half (45 percent) of seniors diagnosed with Alzheimer's disease or their caregivers report being told the diagnosis (as a definitive) by a healthcare provider, compared with 90 percent or more of those diagnosed with cancer and cardiovascular disease. Also for most people the current method of diagnostics can be too expensive, invasive or just not available everywhere.

Fondo Azul.jpg

Our Mision


Our mission is to make Alzheimer's disease and other neurodegenerative disease detection accessible to people everywhere in the world even before the first symptoms arise, enabling early intervention of diseases and empowering physician and patient.

At Neurognos we are working to change the outcome of Alzheimer’s disease by providing the right information at the right time. We are aiming to do this with our proprietary technology that let us identify the early indications of the disease even years before the first cognitive symptoms are detectable.

Our Mision


Our mission is to make Alzheimer's disease and other neurodegenerative disease detection accessible to people everywhere in the world even before the first symptoms arise, enabling early intervention of diseases and empowering physician and patient.

At Neurognos we are working to change the outcome of Alzheimer’s disease by providing the right information at the right time. We are aiming to do this with our proprietary technology that let us identify the early indications of the disease even years before the first cognitive symptoms are detectable.

Iconografía_Laboratorio 4.png

              

At Neurognos, we’re connecting Alzheimers patients with next-generation screening and diagnostic tests through the power of Machine Learning (ML). Decoding hidden patterns by using artificial intelligence (AI) to recognize disease-associated patterns among circulating biomarkers, Neurognos is developing simple, accurate, and noninvasive blood tests for early-Alzheimer's screening and detection. We are looking to provide key information that empowers doctors and patients so they can treat the disease in the most effective way.